BRAVO: High grade bladder cancer: a randomised controlled trial of radical cystectomy against intra-vesical immunotherapy – a feasibility study

Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study (2021)
Journal Article
Brown, J. M., Croft, J., Poad, H., Bell, R., Collinson, M., Gordon, K., Dooldeniya, M., Conroy, S., Catto, J. W., Noon, A. P., Simms, M., Chahal, R., Jain, S., Koenig, P., Johnson, M., Twiddy, M., & Goodwin, L. (2021). Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study. Journal of Clinical Oncology, 39(3), 202-214. https://doi.org/10.1200/JCO.20.01665

PURPOSE: High-grade nonmuscle invasive bladder cancer (HRNMIBC) is a heterogeneous disease. Treatments include intravesical maintenance Bacillus Calmette-Guerin (mBCG) and radical cystectomy (RC). We wanted to understand whether a randomized trial co... Read More about Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study.